BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...Biotechs created or co-founded by Truffle include antiviral play Abivax S.A. (Euronext: ABVX), antibiotics company Deinove S.A....
BioCentury | Jun 18, 2018
Preclinical News

Researchers identify new class of antimicrobials

...Researchers from Technical University Berlin and the Deinobiotics subsidiary of Deinove S.A. (Euronext:ALDEI) identified a new class...
...to further investigate the compounds' mechanism of action to develop them as antimicrobial drugs. Elizabeth S. Eaton Deinobiotics Deinove S.A. Technical...
BioCentury | Apr 1, 2013
Company News

Deinove infectious, agbio/environmental news

...from the Deinococci bacteria. Deinove, which owns 49% of Deinobiotics, granted the subsidiary rights to Deinove's...
...Deinove has the option to buy back all Deinobiotics shares sold to the holding company. Deinove...
...is the founder of Novoxel, which AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) acquired in 2010. Deinove S.A....
BioCentury | Jan 14, 2013
Company News

Deinove management update

Deinove S.A. (Euronext:ALDEI), Paris, France Business: Agbio/Environmental, Infectious Hired: Emmanuel Petiot as CEO, formerly director of North American sales at Novozymes A/S ; he succeeds Jacques Biton, who becomes chairman of the scientific advisory board...
BioCentury | Jun 6, 2011
Company News

Deinove, OSEO deal

...Deinococcus bacteria. The milestone was triggered by the selection of a thermophilic Deinococcus base strain. Deinove...
...under the deal so far, is eligible for about €2.6 ($3.7 million) in additional milestones. Deinove S.A....
BioCentury | Jan 17, 2011
Company News

Deinove management update

Deinove S.A. (Euronext:ALDEI), Paris, France Business: Agbio/Environmental, Infectious Hired: Michael Krel as EVP of business development, a newly created position, formerly business development manager at Metabolic Explorer S.A. WIR Staff Infectious...
BioCentury | Jul 5, 2010
Finance

3Q Financial Markets Preview: Summer scrapes bottom

...Inc. (NASDAQ:ALIM) 4/22/10 $72.1 $341.6 $231.0 -32% Codexis Inc. (NASDAQ:CDXS) 4/22/10 $78.0 $441.7 $297.6 -33% Deinove S.A....
BioCentury | Jun 28, 2010
Finance

More Alternext

...autoimmune and inflammation company Neovacs S.A. raised 10 million ($13.6 million) followed by bioprocessing play Deinove S.A....
BioCentury | Apr 26, 2010
Financial News

Deinove completes IPO

Deinove S.A. (Euronext:ALDEI), Paris, France Business: Agbio/Environmental, Infectious Date completed: 4/21/10 Type: IPO Raised: €12.1 million ($16.2 million) Shares: 1.4 million Price: €8.33 Shares after offering: 4.8 million Underwriters: Dexia Securities; Invest Securities Overallotment: 248,499...
BioCentury | Apr 26, 2010
Finance

French get a break

...Bioprocessing play Deinove S.A. is the second biotech in as many weeks to go public on Alternext...
...which became the home of small companies with little financial or research momentum. Last week, Deinove...
...is doing reasonably well as a market with liquidity," he said. As for Neovacs and Deinove...
Items per page:
1 - 10 of 17
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

...Biotechs created or co-founded by Truffle include antiviral play Abivax S.A. (Euronext: ABVX), antibiotics company Deinove S.A....
BioCentury | Jun 18, 2018
Preclinical News

Researchers identify new class of antimicrobials

...Researchers from Technical University Berlin and the Deinobiotics subsidiary of Deinove S.A. (Euronext:ALDEI) identified a new class...
...to further investigate the compounds' mechanism of action to develop them as antimicrobial drugs. Elizabeth S. Eaton Deinobiotics Deinove S.A. Technical...
BioCentury | Apr 1, 2013
Company News

Deinove infectious, agbio/environmental news

...from the Deinococci bacteria. Deinove, which owns 49% of Deinobiotics, granted the subsidiary rights to Deinove's...
...Deinove has the option to buy back all Deinobiotics shares sold to the holding company. Deinove...
...is the founder of Novoxel, which AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.) acquired in 2010. Deinove S.A....
BioCentury | Jan 14, 2013
Company News

Deinove management update

Deinove S.A. (Euronext:ALDEI), Paris, France Business: Agbio/Environmental, Infectious Hired: Emmanuel Petiot as CEO, formerly director of North American sales at Novozymes A/S ; he succeeds Jacques Biton, who becomes chairman of the scientific advisory board...
BioCentury | Jun 6, 2011
Company News

Deinove, OSEO deal

...Deinococcus bacteria. The milestone was triggered by the selection of a thermophilic Deinococcus base strain. Deinove...
...under the deal so far, is eligible for about €2.6 ($3.7 million) in additional milestones. Deinove S.A....
BioCentury | Jan 17, 2011
Company News

Deinove management update

Deinove S.A. (Euronext:ALDEI), Paris, France Business: Agbio/Environmental, Infectious Hired: Michael Krel as EVP of business development, a newly created position, formerly business development manager at Metabolic Explorer S.A. WIR Staff Infectious...
BioCentury | Jul 5, 2010
Finance

3Q Financial Markets Preview: Summer scrapes bottom

...Inc. (NASDAQ:ALIM) 4/22/10 $72.1 $341.6 $231.0 -32% Codexis Inc. (NASDAQ:CDXS) 4/22/10 $78.0 $441.7 $297.6 -33% Deinove S.A....
BioCentury | Jun 28, 2010
Finance

More Alternext

...autoimmune and inflammation company Neovacs S.A. raised 10 million ($13.6 million) followed by bioprocessing play Deinove S.A....
BioCentury | Apr 26, 2010
Financial News

Deinove completes IPO

Deinove S.A. (Euronext:ALDEI), Paris, France Business: Agbio/Environmental, Infectious Date completed: 4/21/10 Type: IPO Raised: €12.1 million ($16.2 million) Shares: 1.4 million Price: €8.33 Shares after offering: 4.8 million Underwriters: Dexia Securities; Invest Securities Overallotment: 248,499...
BioCentury | Apr 26, 2010
Finance

French get a break

...Bioprocessing play Deinove S.A. is the second biotech in as many weeks to go public on Alternext...
...which became the home of small companies with little financial or research momentum. Last week, Deinove...
...is doing reasonably well as a market with liquidity," he said. As for Neovacs and Deinove...
Items per page:
1 - 10 of 17